Skip to main content

Adial Pharmaceuticals, Inc. (ADIL)

NASDAQ: ADIL · IEX Real-Time Price · USD
4.70
+0.03 (0.64%)
After-hours:Sep 24, 2021 7:11 PM EDT
4.67
0.28 (6.38%)
At close: Sep 24, 4:00 PM
Market Cap94.68M
Revenue (ttm)n/a
Net Income (ttm)-16.08M
Shares Out20.45M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,051,451
Open4.66
Previous Close4.39
Day's Range4.41 - 5.08
52-Week Range1.20 - 5.08
Beta0.70
Analystsn/a
Price Target10.00 (+114.1%)
Est. Earnings DateNov 11, 2021

About ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

IndustryPharmaceuticals
IPO DateJul 30, 2018
Employees8
Stock ExchangeNASDAQ
Ticker SymbolADIL
Full Company Profile

Financial Performance

Financial Statements

News

Adial CEO William Stilley Invited to Participate in Maxim Group's Virtual Panel Series Conference: “Disruptors in the...

CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...

1 week ago - GlobeNewsWire

Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...

2 weeks ago - GlobeNewsWire

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with A...

ONWARD trial enrollment closed; trial completion expected in Q1 2022 ONWARD trial enrollment closed; trial completion expected in Q1 2022

3 weeks ago - GlobeNewsWire

Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients ...

On track for trial completion in the first quarter of 2022

1 month ago - GlobeNewsWire

Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive B...

CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

1 month ago - GlobeNewsWire

Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments

CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

1 month ago - GlobeNewsWire

Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Us...

CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

1 month ago - GlobeNewsWire

Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market

Financing fully funds ONWARD™ Phase 3 trial until data read-out Financing fully funds ONWARD™ Phase 3 trial until data read-out

1 month ago - GlobeNewsWire

Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com

CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...

1 month ago - GlobeNewsWire

Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform

Data merits further testing for pain reduction as a possible alternative to opioids

2 months ago - GlobeNewsWire

Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share

CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...

2 months ago - GlobeNewsWire

The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion

Study Drug Continues to Appear to be Well-Tolerated

2 months ago - GlobeNewsWire

Adial Joins Russell Microcap® Index

CHARLOTTESVILLE, Va., June 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

2 months ago - GlobeNewsWire

FDA Denies Adial Pharma's Fast Track Request For AD04 in Alcohol Use Disorder

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder has been denied at this time. The FDA stated that th...

3 months ago - Benzinga

Adial Pharmaceuticals Provides Regulatory and Development Update

CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...

3 months ago - GlobeNewsWire

Top 10 Biotech Penny Stocks to Watch in July 2021

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and...

Other symbols:MNOVOPKVTVT
3 months ago - PennyStocks

Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic...

The Company believes the genetic companion diagnostic test for AD04 for Alcohol Use Disorder represents a multi-billion dollar potential market opportunity The Company believes the genetic companion dia...

3 months ago - GlobeNewsWire

Adial Pharmaceuticals Comments on Article in ‘The Atlantic,' Highlighting the Second Pandemic of Addiction

CHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

3 months ago - GlobeNewsWire

Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share

CHARLOTTESVILLE, Va., June 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

3 months ago - GlobeNewsWire

Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Di...

CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments fo...

4 months ago - GlobeNewsWire

Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel

Discusses long-term effects of COVID-19 pandemic on mental health and addiction Discusses long-term effects of COVID-19 pandemic on mental health and addiction

6 months ago - GlobeNewsWire

Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share

CHARLOTTESVILLE, Va., March 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...

6 months ago - GlobeNewsWire

Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion

CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments f...

6 months ago - GlobeNewsWire

Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants

CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the developmen...

6 months ago - GlobeNewsWire

Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial

CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...

6 months ago - GlobeNewsWire